Anti-CR1L functional antibody

Anti-CR1L functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to CR1L/CR1L products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0121-Ab-1/ GM-Tg-hg-SE0121-Ab-2Anti-Human CR1L monoclonal antibodyHuman
GM-Tg-rg-SE0121-Ab-1/ GM-Tg-rg-SE0121-Ab-2Anti-Rat CR1L monoclonal antibodyRat
GM-Tg-mg-SE0121-Ab-1/ GM-Tg-mg-SE0121-Ab-2Anti-Mouse CR1L monoclonal antibodyMouse
GM-Tg-cynog-SE0121-Ab-1/ GM-Tg-cynog-SE0121-Ab-2Anti-Cynomolgus/ Rhesus macaque CR1L monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0121-Ab-1/ GM-Tg-felg-SE0121-Ab-2Anti-Feline CR1L monoclonal antibodyFeline
GM-Tg-cang-SE0121-Ab-1/ GM-Tg-cang-SE0121-Ab-2Anti-Canine CR1L monoclonal antibodyCanine
GM-Tg-bovg-SE0121-Ab-1/ GM-Tg-bovg-SE0121-Ab-2Anti-Bovine CR1L monoclonal antibodyBovine
GM-Tg-equg-SE0121-Ab-1/ GM-Tg-equg-SE0121-Ab-2Anti-Equine CR1L monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0121-Ab-1/ GM-Tg-hg-SE0121-Ab-2; GM-Tg-rg-SE0121-Ab-1/ GM-Tg-rg-SE0121-Ab-2;
GM-Tg-mg-SE0121-Ab-1/ GM-Tg-mg-SE0121-Ab-2; GM-Tg-cynog-SE0121-Ab-1/ GM-Tg-cynog-SE0121-Ab-2;
GM-Tg-felg-SE0121-Ab-1/ GM-Tg-felg-SE0121-Ab-2; GM-Tg-cang-SE0121-Ab-1/ GM-Tg-cang-SE0121-Ab-2;
GM-Tg-bovg-SE0121-Ab-1/ GM-Tg-bovg-SE0121-Ab-2; GM-Tg-equg-SE0121-Ab-1/ GM-Tg-equg-SE0121-Ab-2
Products NameAnti-CR1L monoclonal antibody
Formatmab
Target NameCR1L
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CR1L benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0121-Ag-1Recombinant multi-species CR1L protein
    ORF Viral VectorpGMLPm004198mouse Cr1l Lentivirus plasmid
    ORF Viral VectorvGMLPm004198mouse Cr1l Lentivirus particle


    Target information

    Target IDGM-SE0121
    Target NameCR1L
    Gene ID1379,12946,54243,102899461,106783153
    Gene Symbol and SynonymsCr1,CR1L,Crry,Mcp,mCRY
    Uniprot AccessionQ2VPA4,Q63135
    Uniprot Entry NameCR1L_HUMAN,CR1L_RAT
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000197721
    Target ClassificationN/A

    The target: CR1L, gene name: CR1L, also named as . Acts upstream of or within regulation of complement activation and regulation of complement-dependent cytotoxicity. Part of receptor complex. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.